Summary PD-1/PD-L1–targeted immunotherapy has emerged as a promising therapeutic
strategy for pulmonary adenocarcinoma (pADC). Epithelial-to-mesenchymal transition (EMT)
is involved in the progression and immune evasion of cancers. Therefore, we investigated
the association between PD-L1 expression and EMT phenotype in pADC.
Immunohistochemistry for E-cadherin (epithelial marker), ZEB1, SNAIL, SLUG, vimentin
(mesenchymal markers), PD-L1, CD8, and PD-1 was performed on 477 cases of pADC …